A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: Trial IND.186

David A. Macdonald; Sarit E. Assouline; Joseph Brandwein; Suzanne Kamel-Reid; Elizabeth A. Eisenhauer; Stephen Couban; Stephen Caplan; Alison Foo; Wendy Walsh; Brian Leber

doi:10.3109/10428194.2012.737917

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: Trial IND.186

David A. Macdonald, Sarit E. Assouline, Joseph Brandwein, Suzanne Kamel-Reid, Elizabeth A. Eisenhauer, Stephen Couban, Stephen Caplan, Alison Foo, Wendy Walsh, Brian Leber

科研成果: 期刊稿件 › 文章 › 同行评审

40 引用（Scopus）

源语言	英语
页（从-至）	760-766
页数	7
期刊	Leukemia and Lymphoma
卷	54
期	4
DOI	https://doi.org/10.3109/10428194.2012.737917
出版状态	已出版 - 4月 2013
已对外发布	是

!!!ASJC Scopus Subject Areas

血液学
肿瘤学
癌症研究

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.3109/10428194.2012.737917

其它文件与链接

指纹

探究 'A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: Trial IND.186' 的科研主题。它们共同构成独一无二的指纹。

引用此

Macdonald, D. A., Assouline, S. E., Brandwein, J., Kamel-Reid, S., Eisenhauer, E. A., Couban, S., Caplan, S., Foo, A., Walsh, W., & Leber, B. (2013). A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: Trial IND.186. Leukemia and Lymphoma, 54(4), 760-766. https://doi.org/10.3109/10428194.2012.737917

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: Trial IND.186. / Macdonald, David A.; Assouline, Sarit E.; Brandwein, Joseph 等.
在: Leukemia and Lymphoma, 卷 54, 号码 4, 04.2013, 页码 760-766.

科研成果: 期刊稿件 › 文章 › 同行评审

Macdonald, DA, Assouline, SE, Brandwein, J, Kamel-Reid, S, Eisenhauer, EA, Couban, S, Caplan, S, Foo, A, Walsh, W & Leber, B 2013, 'A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: Trial IND.186', Leukemia and Lymphoma, 卷 54, 号码 4, 页码 760-766. https://doi.org/10.3109/10428194.2012.737917

Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S 等. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: Trial IND.186. Leukemia and Lymphoma. 2013 4月;54(4):760-766. doi: 10.3109/10428194.2012.737917

Macdonald, David A. ; Assouline, Sarit E. ; Brandwein, Joseph 等. / A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group : Trial IND.186. 在: Leukemia and Lymphoma. 2013 ; 卷 54, 号码 4. 页码 760-766.

@article{8f1e670829774473b34fe7893ded7072,

title = "A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: Trial IND.186",

author = "Macdonald, {David A.} and Assouline, {Sarit E.} and Joseph Brandwein and Suzanne Kamel-Reid and Eisenhauer, {Elizabeth A.} and Stephen Couban and Stephen Caplan and Alison Foo and Wendy Walsh and Brian Leber",

note = "Funding Information: This trial was supported in part by the Canadian Cancer Society Research Institute core grant to the NCIC Clinical Trials Group and by a research grant from Bayer Inc., Toronto, Canada.",

year = "2013",

month = apr,

doi = "10.3109/10428194.2012.737917",

language = "English",

volume = "54",

pages = "760--766",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group

T2 - Trial IND.186

AU - Macdonald, David A.

AU - Assouline, Sarit E.

AU - Brandwein, Joseph

AU - Kamel-Reid, Suzanne

AU - Eisenhauer, Elizabeth A.

AU - Couban, Stephen

AU - Caplan, Stephen

AU - Foo, Alison

AU - Walsh, Wendy

AU - Leber, Brian

N1 - Funding Information: This trial was supported in part by the Canadian Cancer Society Research Institute core grant to the NCIC Clinical Trials Group and by a research grant from Bayer Inc., Toronto, Canada.

PY - 2013/4

Y1 - 2013/4

UR - http://www.scopus.com/inward/record.url?scp=84879150977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879150977&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.737917

DO - 10.3109/10428194.2012.737917

M3 - Article

C2 - 23061485

AN - SCOPUS:84879150977

SN - 1042-8194

VL - 54

SP - 760

EP - 766

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 4

ER -